Empowered Funds LLC Sells 25,412 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Empowered Funds LLC lowered its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 51.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,229 shares of the biotechnology company's stock after selling 25,412 shares during the period. Empowered Funds LLC owned 0.05% of United Therapeutics worth $8,682,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. ClariVest Asset Management LLC increased its position in shares of United Therapeutics by 120.0% in the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company's stock worth $25,000 after purchasing an additional 42 shares during the last quarter. V Square Quantitative Management LLC purchased a new stake in shares of United Therapeutics during the 2nd quarter valued at $30,000. Innealta Capital LLC bought a new stake in shares of United Therapeutics during the 2nd quarter worth $33,000. USA Financial Formulas purchased a new position in United Therapeutics in the third quarter worth $33,000. Finally, Capital Performance Advisors LLP bought a new position in United Therapeutics in the third quarter valued at $82,000. Institutional investors own 94.08% of the company's stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on UTHR. Jefferies Financial Group raised their target price on shares of United Therapeutics from $315.00 to $432.00 and gave the stock a "buy" rating in a report on Monday, September 23rd. TD Cowen raised their price target on shares of United Therapeutics from $350.00 to $400.00 and gave the stock a "buy" rating in a report on Monday, October 21st. Oppenheimer boosted their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the company an "outperform" rating in a research report on Thursday, October 31st. LADENBURG THALM/SH SH increased their target price on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. Finally, StockNews.com upgraded United Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Thursday, October 17th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $370.86.

Insider Activity

In related news, CEO Martine A. Rothblatt sold 3,600 shares of the stock in a transaction on Monday, August 19th. The stock was sold at an average price of $344.18, for a total transaction of $1,239,048.00. Following the sale, the chief executive officer now directly owns 130 shares of the company's stock, valued at $44,743.40. This trade represents a 96.51 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Nilda Mesa sold 224 shares of the business's stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $412.28, for a total value of $92,350.72. Following the completion of the transaction, the director now directly owns 5,783 shares of the company's stock, valued at approximately $2,384,215.24. This trade represents a 3.73 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 113,396 shares of company stock worth $42,175,418 over the last three months. 11.90% of the stock is currently owned by corporate insiders.

United Therapeutics Price Performance

NASDAQ:UTHR traded down $23.02 during mid-day trading on Friday, hitting $363.25. 619,978 shares of the company's stock were exchanged, compared to its average volume of 371,282. The company has a market cap of $16.22 billion, a PE ratio of 15.95, a P/E/G ratio of 1.13 and a beta of 0.56. United Therapeutics Co. has a one year low of $208.62 and a one year high of $417.82. The business has a fifty day moving average price of $362.93 and a 200 day moving average price of $328.17.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, topping the consensus estimate of $6.16 by $0.23. The company had revenue of $748.90 million for the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm's quarterly revenue was up 22.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $5.38 EPS. On average, equities analysts forecast that United Therapeutics Co. will post 25.1 EPS for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.